

AngioDynamics Named to Forbes 200 Best Small Companies List

QUEENSBURY, N.Y., Oct 18, 2006 (BUSINESS WIRE) -- AngioDynamics, Inc. (NASDAQ:ANGO) today announced that it was named to the list of the 200 Best Small Companies in America published in the October 30, 2006 issue of Forbes. AngioDynamics was #11 on this prestigious list and was also recognized as one of the best newcomers to Forbes' annual publication.

According to Forbes, selected companies have revenues between \$5 million and \$750 million, a share price above \$5 as of Sept. 29, 2006, profit margins of better than 5%, and positive sales and profit growth over both the last twelve months and the last five years.

Eamonn P. Hobbs, president and chief executive officer of AngioDynamics, commented, "It is a great honor to be recognized for the success we have had in growing our medical device business. We are thrilled to be selected to this list along with other emerging US companies."

The article may be accessed on Forbes web site at www.forbes.com/200best.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic products and accessories, dialysis products, vascular access products, PTA products, drainage products, thrombolytic products and venous products. More information is available at www.angiodynamics.com.

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended June 3, 2006, may affect the actual results achieved by the Company.

SOURCE: AngioDynamics, Inc.

AngioDynamics, Inc.

Jennifer Chatt, 800-772-6446 x127

www.angiodynamics.com

or

Lippert/Heilshorn & Associates, Inc.

Kim Sutton Golodetz, 212-838-3777

kgolodetz@lhai.com

Bruce Voss, 310-691-7100

bvoss@lhai.com